Article PDF
Avoid common mistakes on your manuscript.
References
Mazzola, A., Todesco, E., Drouin, S., Hazan, F., Marot, S., Thabut, D., Varnous, S., Soulié, C., Barrou, B., Marcelin, A.G., et al. (2022). Poor antibody response after two doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in transplant recipients. Clin Infect Dis 74, 1093–1096.
McCormack, F.X., Inoue, Y., Moss, J., Singer, L.G., Strange, C., Nakata, K., Barker, A.F., Chapman, J.T., Brantly, M.L., Stocks, J.M., et al. (2011). Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364, 1595–1606.
Gupta, N., Finlay, G.A., Kotloff, R.M., Strange, C., Wilson, K.C., Young, L.R., Taveira-DaSilva, A.M., Johnson, S.R., Cottin, V., Sahn, S.A., et al. (2017). Lymphangioleiomyomatosis diagnosis and management: High-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official american thoracic society/Japanese respiratory society clinical practice guideline. Am J Respir Crit Care Med 196, 1337–1348.
Johnson, S.R., Cordier, J.F., Lazor, R., Cottin, V., Costabel, U., Harari, S., Reynaud-Gaubert, M., Boehler, A., Brauner, M., Popper, H., et al. (2010). European respiratory society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respiratory J 35, 14–26.
Skowronski, D.M., Setayeshgar, S., Febriani, Y., Ouakki, M., Zou, M., Talbot, D., Prystajecky, N., Tyson, J.R., Gilca, R., Brousseau, N., et al. (2021). Two-dose SARS-COV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: Test-negative design studies from British Columbia and Quebec, Canada. MedRxiv doi: https://doi.org/10.1101/2021.10.26.21265397.
Zhang, H., Jia, Y., Ji, Y., Cong, X., Liu, Y., Yang, R., Kong, X., Shi, Y., Zhu, L., Wang, Z., et al. (2021). Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world. MedRxiv doi: https://doi.org/10.1101/2021.08.18.21262214.
Courtwright, A.M., Goldberg, H.J., Henske, E.P., and El-Chemaly, S. (2017). The effect of mtor inhibitors on respiratory infections in lymphangioleiomyomatosis. Eur Respir Rev 26, 160004.
Keating, R., Hertz, T., Wehenkel, M., Harris, T.L., Edwards, B.A., McClaren, J.L., Brown, S.A., Surman, S., Wilson, Z.S., Bradley, P., et al. (2013). The kinase mtor modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol 14, 1266–1276.
Mannick, J.B., Del Giudice, G., Lattanzi, M., Valiante, N.M., Praestgaard, J., Huang, B., Lonetto, M.A., Maecker, H.T., Kovarik, J., Carson, S., et al. (2014). Mtor inhibition improves immune function in the elderly. Sci Transl Med 6, 268ra179.
Mannick, J.B., Morris, M., Hockey, H.U.P., Roma, G., Beibel, M., Kulmatycki, K., Watkins, M., Shavlakadze, T., Zhou, W., Quinn, D., et al. (2018). Torc1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med 10, eaaq1564.
Acknowledgements
This work was supported by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS 2021-I2M-1-003), the National Natural Science Foundation of China (U20A20341), and the Beijing Science and Technology Plan (Z211100002521024). We thank Mr. Xiaokai Xia from Shanghai Geneodx Biotech for his kind assistance and support. We thank Professors Yushi Zhang, Jiaolin Zhou, and Fengzhi Feng from Peking Union Medical College Hospital for their discussion and support.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Compliance and ethics The author(s) declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Cheng, C., Wang, Y., Hu, D. et al. Humoral response to inactivated SARS-CoV-2 vaccines in patients on sirolimus alone. Sci. China Life Sci. 65, 2118–2120 (2022). https://doi.org/10.1007/s11427-022-2102-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-022-2102-3